Tags

Type your tag names separated by a space and hit enter

Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
Br J Cancer 1983; 48(5):657-63BJ

Abstract

Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

6315040

Citation

Ahmedzai, S, et al. "Anti-emetic Efficacy and Toxicity of Nabilone, a Synthetic Cannabinoid, in Lung Cancer Chemotherapy." British Journal of Cancer, vol. 48, no. 5, 1983, pp. 657-63.
Ahmedzai S, Carlyle DL, Calder IT, et al. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48(5):657-63.
Ahmedzai, S., Carlyle, D. L., Calder, I. T., & Moran, F. (1983). Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. British Journal of Cancer, 48(5), pp. 657-63.
Ahmedzai S, et al. Anti-emetic Efficacy and Toxicity of Nabilone, a Synthetic Cannabinoid, in Lung Cancer Chemotherapy. Br J Cancer. 1983;48(5):657-63. PubMed PMID: 6315040.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. AU - Ahmedzai,S, AU - Carlyle,D L, AU - Calder,I T, AU - Moran,F, PY - 1983/11/1/pubmed PY - 1983/11/1/medline PY - 1983/11/1/entrez SP - 657 EP - 63 JF - British journal of cancer JO - Br. J. Cancer VL - 48 IS - 5 N2 - Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use. SN - 0007-0920 UR - https://www.unboundmedicine.com/medline/citation/6315040/Anti_emetic_efficacy_and_toxicity_of_nabilone_a_synthetic_cannabinoid_in_lung_cancer_chemotherapy_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/6315040/ DB - PRIME DP - Unbound Medicine ER -